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Abstract
Rett syndrome (RTT) is a monogenic rare disorder that causes severe neurological problems. In
most cases, it results from a loss-of-function mutation in the gene encoding methyl-CPG-binding
protein 2 (MECP2). Currently, about 900 uniqueMECP2 variations (benign and pathogenic) have
been identified and it is suspected that the different mutations contribute to different levels of
disease severity. For researchers and clinicians, it is important that genotype–phenotype infor-
mation is available to identify disease-causing mutations for diagnosis, to aid in clinical manage-
ment of the disorder, and to provide counseling for parents. In this study, 13 genotype–phenotype
databases were surveyed for their general functionality and availability of RTT-specific MECP2
variation data. For each database, we investigated findability and interoperability alongside prac-
tical user functionality, and type and amount of genetic and phenotype data. Themain conclusions
are that, as well as being challenging to find these databases and specific MECP2 variants held
within, interoperability is as yet poorly developed and requires effort to search across databases.
Nevertheless, we found several thousand online database entries forMECP2 variations and their
associated phenotypes, diagnosis, or predicted variant effects, which is a good starting point for
researchers and clinicians whowant to provide, annotate, and use the data.
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1 INTRODUCTION
Rett syndrome (RTT; MIM# 312750) is one of 5,000–8,000 known
rare diseases that together have been identified as affecting 6%–8%
of the world's population. Approximately 80% of these diseases have
a genetic origin (Council Recommendation on an action in the field of
rare diseases (2009/C 151/02), Recital 5). Most of these diseases are
caused by pathological variants in one single, disease-specific gene. In
the case of RTT, this is in MECP2, an important regulator of neuronal
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in anymedium, provided
the original work is properly cited.
c© 2018 The Authors.HumanMutation published byWiley Periodicals, Inc.
development and function (Ehrhart et al., 2016; Lyst & Bird, 2015).
At the present time, around 900 unique variations in MECP2 have
been identified (Gold, Krishnarajy, Ellaway, & Christodoulou, 2018).
To help distinguish between pathological and neutral genetic variants
(Hunter et al., 2016), scientists and clinicians collect genetic data and
corresponding phenotypic information and make this information
available in databases, which can be used for research and prognostic
purposes. In this respect, RTT serves as an example for any monogenic
rare disease where, due to the limited number of individuals, a better
914 wileyonlinelibrary.com/journal/humu HumanMutation. 2018;39:914–924.
TOWNEND ET AL. 915
understanding of the disease can be reached through combining data
from different databases that may be housed at different institutions
and in different countries. In recent years, the European Union's
policy on rare diseases (e.g., Directive 2011/24/EU) has recognized
the value of sharing information, knowledge and expertise, and
has generated a number of initiatives to encourage pan-European
collaboration, for example, through the creation of European Refer-
ence Networks (ERNs) such as Intellectual disability TeleHealth And
Congenital Anomalies (ITHACA), the ERN focused on rare congenital
malformations and rare intellectual disability in which RTT is placed
(https://ec.europa.eu/health/sites/health/files/ern/docs/ernithaca_
factsheet_en.pdf).
Generally, there are different types of databases for rare diseases:
(1) Patient registries, containing i.a. patient data, genetic data, pheno-
type descriptions and information on medication. These are not nor-
mally open to the public. There are several data platforms, for example,
RD-connect, which host patient registries with controlled access.
(2) Genetic data repositories, for example, EGA (European Genome-
Phenome Archive). These have been increasing in number since next-
generation sequencing (NGS), and especially whole exome sequencing
(WES), has been used as a clinical standard for the diagnosis of rare
disorders and other suspected genetic disorders. (3) Genotype–
phenotype databases that combine genetic data (e.g., DNA sequences,
variants, genotypes) with phenotypic data. (4) Databases that
store general information about genes, proteins, metabolites, their
interactions and their mutation specific aberrations.
It is within this context that rare disease registries and databases
have also been recognized by the European Union as “key instruments
to develop clinical research in the field of rare diseases, to improve
patient care and healthcare planning” (https://ec.europa.eu/health/
rare_diseases/policy/registries_en).
This study focusses on the genotype–phenotype databases. Several
such databases have been developed and will be discussed here.
The fundamental goal of these databases is to collect and provide
access to data and knowledge to promote research into the func-
tional and pathogenic significance of genetic variants (Brookes &
Robinson, 2015; Johnston & Biesecker, 2013). Critical for accurate
analysis is the ability to distinguish between the disease-causing alleles
and the abundance of benign variants or less important functional
variants that co-occur in both normal and disease-affected individuals.
One consequence of the increased power of NGS—often used for
gene panels, WES, and whole genome sequencing (WGS)—is the
increased danger of incorrect assignment of pathogenicity, when
compared with single gene analysis. For instance, a typical WES (e.g.,
in the context of suspected diagnosis of a rare monogenic disorder)
may uncover up to 25,000 variants (Gilissen, Hoischen, Brunner, &
Veltman, 2012). Elucidation of just a handful of pathogenic variants
from the resulting thousands continues to be a major challenge in
spite of the availability of standardized software solutions. The most
effectiveway to start distinguishing benign frompathogenic variants is
based on population frequencies of variants. In this approach, all vari-
ants occurring in the population at higher frequencies than the disease
prevalence are considered benign. From the many recent initiatives to
collect exomevariants of individualswithout clear disease phenotypes,
the Exome Aggregation Consortium (ExAC) is the largest, containing
more than 60,000 exomes (Exome_Aggregation_Consortium, Lek, &
MacArthur, 2015). In general, the population frequency information
will reduce the number of candidate (pathogenic) mutations to a
couple of hundred (Gilissen et al., 2012). Further prioritization can
then take place by employing tools such as PolyPhen and SIFT (Sorting
Intolerant From Tolerant). Ensembl's Variant Effect Predictor tool
(Lelieveld, Veltman, & Gilissen, 2016) makes these aforementioned
classic approaches available; it also includes a number of newer
methods to distinguish between pathogenic, implicated, associated,
damaging, and deleterious variants, and/or those of unknown sig-
nificance among the remaining variants. These next steps in the
prioritization process are summarized by Lelieveld et al. (2016). The
challengeof distinguishing disease-causing sequence variants from the
many potentially functional variants in any human genome recently
promptedMacArthur et al. (2014) to propose guidelines for investigat-
ing causality of sequence variants in human disease. The proper setup
and use of databases is one of the key issues they identified in order to
be able to upload, store and find pathogenic and benign variants.
The results of the analysis of disease-causing variants also provides
vital information, not just for scientists and researchers who are seek-
ing to further knowledge andunderstanding of certain diseases, but for
clinicians to make the correct diagnosis and provide genetic counsel-
ing and patient care. State of the art genotype–phenotype databases
are of particular value, and among these, the so-called locus-specific
mutation databases (LSDBs) (e.g., LOVD (Fokkema et al., 2011)) have
served diagnosticians for many years by facilitating the interpreta-
tions of genetic variants (Brookes & Robinson, 2015; Johnston &
Biesecker, 2013). In addition to the LSDBs, a variety of other (clini-
cally relevant) databases with a focus on genotype–phenotype rela-
tionships has emerged in recent years (Lelieveld et al., 2016) and the
need to integrate information from these databases has also gener-
ated many initiatives. The RD-Connect project provides a platform
for the rare disease community to find and share data and tools
(Thompson et al., 2014). It includes a pipeline to harmonize variant
annotation of rare disease genomes (Laurie et al., 2016), registries
of rare disease registries and biobanks (Gainotti et al., submitted),
and bioinformatics tools. It is developed in collaboration with infras-
tructures such as ELIXIR (https://www.elixir-europe.org/), BBMRI-
ERIC (https://www.bbmri-eric.eu/ (Mayrhofer, Holub, Wutte, & Litton,
2016)), the infrastructure consortium for biobanks, and the Global
Alliance for Genomics and Health (GA4GH, https://genomicsand
health.org). The creationofGA4GH in2013 represents oneof themost
prominent large-scale initiatives in this area. The goals and progress of
this groupwere published recently (GA4GH, 2016)
To support both clinicians and researchers, we present in this article
an overview of a number of current genotype–phenotype databases.
We evaluate their general structure and function for use in biomedical
research, especially for researchers/clinicians who want to find “their”
mutation or intend to find a database inwhich to store their genotype–
phenotype data. We give an indication of the findability and interop-
erability, the practical user functionality (up and download functions),
the type and quantity of genotype and phenotype data available, and
provide suggestions for future improvement.
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2 MATERIALS AND METHODS
2.1 Selection of databases
The databases and meta/integrated databases in this survey were
selected according to the following criteria:
1. The database contains genetic variation and associated phenotypic
information (genotype–phenotype databases);
2. The genetic data are available in a processed form to enable a direct
search for variations in a specific gene, region, or disease (e.g., in
the HGVS or reference SNP (rs) format, an identifier given by the
database dbSNP);
3. The database is available online (with orwithout prior registration);
4. The database is available in English.
We do not claim complete coverage of all available databases; we
focus on those which were findable online using search engines (e.g.,
Google) or listed in FairSharing.org (formerly knownasBioSharing.org)
or other meta-databases (RD-connect, bioCADDIE). We evaluated
as a separate category certain meta or integrated databases, which
in themselves contain no new or unique information, but instead
try to integrate information from others. However, a number of
RTT-specific databases, akin to patient registries, were not included
in our evaluation as they require membership of the consortium and
an agreement to input data to the database, or they grant permission
on a case-by-case basis when the request to access data is part of a
specific research project with prior approval from a medical ethical
board. In some instances, a minimal level of data is accessible to qual-
ified researchers through already existing data-sharing rules. These
include the database associated with the longitudinal, population-
based Australian Rett Syndrome Study (AussieRett) (https://rett.
telethonkids.org.au/about/aussierett/, (Downs & Leonard, 2013)),
the International Rett Syndrome Database (InterRett) (https://rett.
telethonkids.org.au/about/interrett/, https://interrett.ichr.uwa.edu.
au//output/index.php, (Louise et al., 2009)), the Rett Database Net-
work (https://www.rettdatabasenetwork.org, (Grillo et al., 2012)), and
the database generated by the US Rett Syndrome Natural History
Study (NHS) (https://www.rettsyndrome.org/research/clinical-trials/
natural-history-study) (Neul et al., 2014). These databases generally
contain cross-sectional and longitudinal natural history data that
has been directly acquired from or input by individuals and their
families, either by families completing a questionnaire or through
direct examination of the individual by a clinician experienced in RTT.
Such methods of data collection differ from the genotype–phenotype
databases of interest in this article.
2.2 Assessment of database properties and
functions
2.2.1 Aspects of FAIR
The FAIR metrics are not yet fully developed (Schultes et al., in prepa-
ration) but as several of these aspects are interesting for the purposes
of our evaluation we checked whether each database meets the basic
FAIR principles described by Wilkinson et al. (2016). These principles
define that data is: (i) *findable* if data or meta data are assigned
unique identifiers, described with rich metadata, and registered or
indexed in a searchable resource; (ii) *accessible* if the data are retriev-
able by their identifiers via a standardized communication protocol,
the protocol itself is open, free, universally implementable and allows
authentication and authorization, whilst, to prevent data being lost,
metadata continues to be accessible even when the data is no longer
available; (iii) *interoperable* if a suitable language for knowledge pre-
sentation and an established vocabulary (e.g., ontologies) are used,
and, ideally, the (meta)data include references to other data; and (iv)
*reusable* if a clear and accessible data usage license is available, the
data are correctly and sufficiently described using domain-relevant
community standards, and data origin and history are included.
2.2.2 Upload and download functions
To investigate user functionality, we looked especially at the upload
and download functions of each database. The upload functions were
typically found in separate “submit” pages or information was given on
how or to whom the data should be sent. For download functionality
we checked whether we could manually download search results, for
example, a list ofMECP2 variants, and which formats were possible for
this. Additionally, we looked for the API description (if available).
2.2.3 Form of genetic and phenotypic data
Each databasewas investigated for the form inwhich genetic variation
(e.g., HGVS or rs) and phenotype information (e.g., diagnosis, predicted
pathogenicity scores, HPO terms etc.) is stored.
2.3 Assessment of RTT/MECP2 specific content
2.3.1 Total numbers ofMECP2 variants in the database
The total number of entries for (unique) MECP2 variants, or variants
which are associated with RTT, was assessed in each database (status
March 2018).
2.3.2 Availability of five selected test variants
To examine the coverage ofMECP2 variants in more detail, fiveMECP2
mutations were selected and used to perform test searches within
each database (Table 1). We decided upon three “classical” variants:
first, a well-known and well-described mutation—an MBD hotspot
mutation—published by Zappella, Meloni, Longo, Hayek, & Renieri
(2001) and reviewed by Lyst & Bird (2015); and, second and third
respectively, two of the most frequently reported nonsense and mis-
sense mutations. Finally, two mutations that were discovered more
recently by WES and WGS: a 23 bp deletion in the C-terminus of
MECP2, reported by Rauch et al. (2012) after performing WES in a
girl displaying a RTT-phenotype; and, an intra-exonic deletion, taken
from Gilissen et al. (2014), after WGS in a person described as hav-
ing severe intellectual disability (IQ<50), a commonly reported clinical
phenotype of RTT (Zoghbi, 2016). The appearance of each of these five
mutations in the selected databases was investigated.
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TABLE 1 MECP2mutations selected for test database searches
Variant 1 Variant 2 Variant 3 Variant 4 Variant 5
Source MBDhotspot
mutation from
(Zappella et al.,
2001)
Frequently
reported
nonsense
mutation
Frequently
reported
missense
mutation
WES variant from (Rauch
et al., 2012)
WGS variant from (Gilissen
et al., 2014)
Genomic level
(GRCh37)a
g.153296882G>A g.153296777G>A g.153296363G>A g.153296093_153296115del g.153295929_153296514del
RNA level
(NM_004992.3)
c.397C>T c.502C>T c.916C>T c.1200_1222del c.765_1350del
Protein level p.(Arg133Cys) p.(Arg168*) p.(Arg306Cys) p.(Pro401Argfs*8) p.(Lys256Asnfs*31)
aThe current genome build at the time of writing this article is GRCh38, but most databases were using GRCh37. ForMECP2, there is a difference ranging
from735 to 659 kbp.
3 RESULTS
We identified nine standalone databases and four meta/integrated
databases for evaluation (Table 2) and collected information by
exploring their content.We checked for general database features and
RTT-specific entries. In detail, we analyzed (a) the FAIR status, (b) the
upload and download possibilities, (c) form of phenotype and genotype
information, (d) the total number of entries relating to theMECP2 gene
or RTT, and (e) the coverage for the chosenMECP2mutations.
3.1 Database properties
3.1.1 Aspects of FAIR
In general, the genetic variation or location databases were easier to
find than the RTT-specific ones. Using Google as the search engine
for “Rett syndrome database” only RettBase (Christodoulou, Grimm,
Maher, & Bennetts, 2003; Krishnaraj, Ho, & Christodoulou, 2017)
or excluded databases such as InterRett and the Rett Syndrome
Database Network (both of which do not allow direct online access to
genotype–phenotype information) were immediately findable—and
several publications about RTT databases (e.g., about the Italian Rett
database and biobank (Sampieri et al., 2007)). Using more generic
terms like “genotype phenotype database” dbGAP (which is an archive
for genotype–phenotype studies), DECIPHER and DisGeNET were
found. Amore specific search result was yielded usingmeta-databases
for biomedical databases. Seven of the databases were findable
on FairSharing.org using the tags “rare disease”, “genetic variation”,
or “phenotype”. Others were mentioned in previous publications
(Lelieveld et al., 2016) or found through personal recommendation
within the scientific community. Considering findability of variants
within the database, most offered the possibility to search for vari-
ants using at least one of the nomenclatures recommended by the
guidelines of the HGVS for genome, RNA or protein changes, or by
rs identifiers. The Korean Mutation Database provided no option to
search for specific variants, only searches by disease (or disease iden-
tifier) were possible. In most cases the databases investigated were
publicly accessible; several, however, restricted access to members
only (e.g., parts of Café Variome) or were commercial databases with
pay to view content (HGMD) (Table 3).
FAIRness, for human users, was hindered by a variety of factors.
For example, while many databases provided a search function, one of
the core aspects of “F”—that data records are uniquely identified—was
frequently overlooked by providers. Often, there was found to be
a preference for embedded javascript/AJAX “reveals” of otherwise
unidentified data, and/or incremental drill-down searches until only
one result remained. Furthermore, impediments to the “I” and “R”
elements of FAIRness—Interoperability and Reusability—were evi-
dent in the sparse use of ontological terms, use of ontological terms
without indicating their source ontology, and lack of easy-to-find
citation information for individual data points within aggregate data.
On the positive side of FAIRness for humans, however, the terms of
data access and re-use, for example, licensing and use for further
studies, were reasonably well implemented in most databases. Not all
data could be accessed and reused but the terms and conditions of use
were clearly presented and a contact person or consortiumwas given.
FAIRness for machines was not evaluated, as, in most cases, the
data providers made little or no effort to support automated accessi-
bility or interoperability. The notable exception was DisGeNET, with
its adoption of nanopublications (data structures that link data, data-
provenance and citation-related information in a manner that can eas-
ily be interpreted by machines (Mons et al., 2011)), and provision of a
SPARQL (SPARQL Protocol and RDFQuery Language) query interface
for these nanopublications (Fu et al., 2015). Where available, a link to
each database's API is given in Table 3.
3.1.2 Up and download functionality
It was possible to download or export search results as txt, CSV, RDF,
XML, or other formats in ClinVar, EVS, EVA, ExAC, Café Variome,
dbSNP, dbVAR, and DisGeNET (Table 3). For DECIPHER, the export-
ing of data to a file was possible upon request, and in HGMD for
paying users. Several databases were found to encourage and accept
data submission and provide upload functions or submission contacts.
However, others were more restricted in this. For example, DisGeNET
retrievesdata fromother (curated) databases anddoesnot allowdirect
upload, EVS and ExAC have a defined list of sources (e.g., projects)
from which the data is provided, and HGMD has its own data retrieval
pipeline.
3.1.3 Genotype and phenotype information format
Currently, there are two major forms in which genetic variants
are given in databases: HGVS nomenclature and rs identifier. Four
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TABLE 2 Overview of databases included in the review
Database and link Contact
How to cite (literature
reference for database) Short description
RTT-specific database
RettBase Prof. John Christodoulou and
Rahul Krishnaraj
Christodoulou et al. (2003) Specific focus on RTT.
Database of genetic information about RTT
patients.
Containsmutation information aboutMECP2 as
well as CDKL5 and FOXG1which cause
different syndromes (formerly named Rett-like
syndromes).
Databases for genetic variations and phenotype information for diseases in general
KMD
KMDRett Syndrome (Korean
Mutation Database)
Contact via KCDC (Korea Centre
for Disease Control and
Prevention)
– Genotype-disease database.
Collection of disease-causing variants in genes.
ClinVar
ClinVar (MECP2)
Mail Landrum et al. (2016) Genotype–phenotype database.
Focus on disease-causing variants in genes.
HGMD “professional” Contact (via publicWebsite) Stenson et al. (2017) Commercial genotype–phenotype database
Databases for all kinds of genetic variations and phenotype information
LOVD
LOVD3.0MECP2 (LeidenOpen
Variation Database)
MECP2 curator: Henk van
Kranen
Fokkema et al. (2011) Genetic variants database.
Locus/gene specific, all genes.
DECIPHER (DatabasE of genomiC
varIation and Phenotype in
Humans using Ensembl
Resources)
Mail Firth et al. (2009) Genotype–phenotype database.
All genes.
EVS
EVS (MECP2) (Exome Variant
Server)
Mail – Genetic variants database.
Originally those which contribute to heart, lung
and blood disorders. Now open to all genes,
linked to dbSNP and dbGAP.
ExAC Browser (Exome Aggregation
Consortium)
Github
Mail
Lek et al. (2016) Database/project to collect and harmonize whole
exome sequencing data.
Allows search for variants at certain locations or
single genes, and direct search for variants.
dbSNP (NCBI Short Genetic
Variations database)
dbSNP (MECP2)
Mail Kitts et al. (2013) Genetic variation database.
Collection of single nucleotide polymorphism
(SNP) and an effect predictor score.
Integrated/meta-databases and genome browsers
dbVAR
dbVAR (MECP2)
Mail Lappalainen et al. (2013),
Phan et al. (2016)
Database for genomic structural variations,
including indels, mobile element insertions,
duplications, inversions, translocations, and
complex chromosomal arrangements.
EVA (European Variation Archive) Mail – Variant browser.
Allows search for variants of specific locations or
genes.
Cafe Variome Mail Lancaster et al. (2015) Meta-database for genetic variants,
genotype-phenotype databases.
Links to 1000Genomes Project, dbSNP,
Diagnostic Variants, DiagnosticMutation
Database, The Frequency of Inherited
Disorders Database, Finnish Disease, FORGE
Canada Consortium, PhenCode, UniProt,
HumanGeneMutation Database,
Locus-specific Databases.
Freely available, but some of the linked databases
content is only available after registration.
DisGeNET Mail Pinero et al. (2015, 2017) Database for gene-disease and variant-disease
associations.
Imports data from curated databases like
Uniprot, ClinVar, GWASCatalog, and so on.
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TABLE 3 Description of database structure and information types
Database
↑Up- and↓Download of dataAPI (if
available) Phenotype information available Genotype information available
RettBase ↑ Submission of data bymail possible
↓No download function,Web
interface
No API or similar
Information onwhether RTT or not,
distinguishes between classical,
atypical, preserved speech, and
forme fruste RTT, mental
retardation (not Rett), Autism
According to HGVS change on the
mRNA/cDNA level, RefSeq
NM_004992 unless stated
otherwise
KMD ↑ Submission of data by registered
users
↓No download function,Web
interface
No API or similar
Diagnosedwith RTT using the
OMIM identifier (=RTT/RTT
preserved speech variant)
According to HGVS change on the
mRNA/cDNA level and RefSeq
ClinVara ↑ Possible, detailed submission
templates and instructions
available
↓Download/export of search results
in form of text files or UI lists
possible
API available here
Information onwhether Pathogenic
or not, Diagnosis, for example,
RTT, Autism, X-linkedmental
retardation
According to HGVS change on the
mRNA/cDNA level (mostly) and
RefSeq
HGMD “professional” ↑Not possible, HGMDhas its own
data acquisition resources
↓Download and export possible (for
registered paying users)
UMLS (ontology)
HPO (ontology)
OMIM
SNOMEDCT
MeSH
Descriptive: e.g. 11 kb deletion in
exon 1–2, HGVS format in the
detailed description
LOVDa ↑Upload possible after registration
with Submitter clearance
↓Download of complete database
possible, not for specific
genes/search results, API available
for LOVD2.0, for LOVD3.0 under
construction
Variant effect predictor: “+”
indicating the variant affects
function, “+?” probably affects
function, “-” does not affect
function, “-?” probably does not
affect function, “?” effect
unknown, “.” effect not classified.
According to HGVS change on the
mRNA/cDNA, DNA and protein
level and RefSeq
DECIPHER ↑Open upload, bulk upload
templates
↓Web interface, and “Anonymised
consentedDECIPHER data can be
made available in the form of a
downloadable encrypted file from
a secure server under a data access
agreement. Please see the section
on data access agreement on the
Data Sharing page.”
API available here
Detailed phenotype description,
using HPO annotations
According to HGVS change on the
mRNA/cDNA level and Ensemble
ID of transcript used (includes
RefSeq)
EVS ↑Data is exclusively fromNHLBI GO
Exome Sequencing Project (ESP)
↓Bulk download files, download of
specific gene variant information
search results as text or VCF
NoAPI or similar
Variant effect prediction by
PolyPhen2
According to HGVS on the
mRNA/cDNA and protein level, rs
IDs
ExACBrowser ↑No upload possible, ExAC includes
data from a list of projects
↓ Export of variation table as CSV
possible
API available here
Variant effect prediction:
Consequence of variation, for
example, intronic variation, and
consequence of protein aa change
rs IDs, genomic position, RefSeq and
allele
dbSNPa ↑ Submission possible either directly
or via EVA, dbGAP or ClinVar
↓ Possible, “Send to file” function for
search results, batch query
function for machine readability
API at NCBI variant reporter
Variant effect prediction,
consequences like, for example,
intronic variation, and
consequence of phenotype, for
example, increased susceptibility
to diseases, is given. No RTT
mutations are yet available.
rs IDs, HGVS (mRNA/cDNA)
dbVARa ↑ Possible, no clinical data (ClinVar),
no sensitive data (dbGAP)
↓”Send-to-file” function
API at NCBI variant reporter
Clinical Assertion:
pathogenic/uncertain significance
rs ID and allele
(Continues)
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TABLE 3 (Continued)
Database
↑Up- and↓Download of dataAPI (if
available) Phenotype information available Genotype information available
EVAa ↑Open to everyone, submission
guidelines
↓ Free - Export function (CSV), API
available here
Variant effect prediction by
PolyPhen2/SIFT
rs IDs and allele
Cafe Variome ↑Upload direct to Café Variome
“hosted” or “in-a-box”
↓ Export of search results in different
formats (CSV, html, LOVD…)
API available here
dbSNP: “phenotype” column, no
entries
HGMD: no phenotype data
Locus specific: no phenotype data
PhenCode: phenotype entry for 1/5
of entries: Diagnosis (RTT, X-linked
mental retardation)
Uniprot: same as PhenCode
dbSNP: HGVS (mRNA/cDNA) allele
and RefSeq,
HGMD: no variant data visible
Locus specific: HGVS (mRNA/cDNA)
allele and RefSeq
PhenCode: HGVS (mRNA/cDNA),
Reference links to original data
source,
Uniprot: HGVS (mRNA/cDNA),
reference links to UniProt ID
DisGeNETa ↑No submission, adding of data by
text mining and other databases
↓Download of search results
possible in different formats
(download page here), provides a
SPARQL endpoint
Diagnosis rs IDs
aFindable at FairSharing.org.
databases give only the rs ID (three of them include the respective
allele), seven (including all Café Variome entries) only HGVS, and two
both (Table 3).
The extent to which phenotype information is given was found
to vary between the different databases (Table 3). Generally, there
is a distinction between diagnosis-based information (six databases
out of 13), phenotype (two, including HPO annotation), and predicted
pathogenicity scores (PolyPhen/SIFT) (six). For example, ClinVar and
PhenCode (PhenCode available via Café Variome) give the clinical
diagnosis (e.g., RTT) including variants (e.g., RTT, preserved speechvari-
ant) while genetic variant databases provide other information. For
example, LOVD, showswhether a variant is pathogenic (severe (+/+) or
minor (−/+)) or not (−/−) based on the PolyPhen score; this is also the
case in EVS. DECIPHER andHGMDprovide detailed phenotypic infor-
mation which is properly annotated using an ontology (HPO). HGMD
in fact provides several options (diagnosis andphenotype).With regard
to the RTT-specific databases, a search of RettBase yielded only infor-
mation on the diagnosis (with variants), but no details about the asso-
ciated phenotype (e.g., epilepsy, scoliosis, medication).
3.2 RTT-specific information
3.2.1 Total number ofMECP2 entries
The greatest number was MECP2 entries were found in RettBase
(4738) (Table 4). dbSNP and LOVD both offer around 4500 entries
(4229 and 4588), ClinVar 1145.Most other databases offer a few hun-
dred MECP2 entries. EVS, EVA, dbSNP, dbVAR, ClinVar, and the ExAC
Browser exchange information. DisGeNET imports information from
ClinVar, so provides nothing new (Table 2).
3.2.2 Availability of the five test variants
We used the mutations listed in Table 1 to perform a test search in the
selected databases. The first three mutations, which are well known,
and in literature well-described mutations (c.397C>T, c.502C>T, and
c.916C>T) were found most abundantly, with over 400 entries in
almost all databases. The fourth (c.1200_1222del) was not found at all,
and the fifth (c.765_1350del) was found only twice, in LOVD (MECP2
gene homepage) and HGMD. These last two are derived from NGS
studies indicating that the data submission pipelines of this data to
genotype-phenotype databases are not yet that well established.
4 DISCUSSION
In this study, we surveyed currently available genotype–phenotype
databases using MECP2 variants in RTT as a test case. We assessed
the database structures and functionality and gave an overview of the
available data onRTT,MECP2 variants and their associated phenotypic
data, with the aim of enabling data producers and data users to select
a databasewhich fits bestwith their needs to store, look up, and re-use
available data.
4.1 Limited availability ofMECP2 gene variants in
databases
Our modest inventory of five different MECP2 variants, of which two
were derived from NGS data, underscores the need for further har-
monization and integration of gene variant information from differ-
ent sources. Through a simple survey, we have shown that coverage of
five selected variants of theMECP2 gene in the databases under inves-
tigation depends upon both their frequency and how long they have
been known. This should not be regarded as a criticism of the indi-
vidual databases for not containing all possible mutations, but rather
as an argument for building a better infrastructure for integration of
novel genome sequencing data into databases and improvement of
interoperability, similar to that offered by the Beacon project in rela-
tion to genomic data. This example of limited coverage in a variety
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TABLE 4 Number of database entries forMECP2 or RTT in general and five specific variants (status March 2018). Number: variant present in
this number,+ variant present, displayedwithout details,− variant not found
Database
Total number of
MECP2 variant
entries
Variant 1
c.397C>T
missense
Variant 2
c.502C>T
nonsense
Variant 3
c.916C>T
missense
Variant 4
c.1200_1222del
Variant 5
c.765_1350del
RettBase 4738 (897 unique) 217 363 246 − −
KoreanMutation Database 35 1 1 1 − −
ClinVar 1145 1 13 13 − −
HGMD “professional”a 975 − + + − +
LOVD3.0MECP2 4588 (807 unique) 197 335 218 − +
DECIPHER 203 6 4 2 − −
EVS 117 − − − − −
ExAC 599 − − − − −
dbSNPa,b,c 4229 + + + − −
dbVARc 469 + + + − −
EVA 378 + + + − −
Cafe Variome – dbSNPa 500 − 1 1 − −
Cafe Variome – PhenCode 809 1 1 1 − −
Cafe Variome –UniProt 71 1 − 1 − −
Cafe Variome –HGMDa 249 − − − − −
Cafe Variome – Locus-specific Databases 10 − − 1 − −
DisGeNETb + + + + − −
adbSNPand theCaféVariome request to dbSNPprovided different numbers forMECP2entries, the same applies for LOVDandHGMD.As theCaféVariome
link uses the public version of HGMD the exact variants are not shown.
bSearch was done via rs number which does not give the exact variation, only position.
cThe numbers for dbSNP and dbVAR are fromNCBI's Variation Viewer forMECP2 (GRCh37.p13).
of databases illustrates the fact that despite much progress in NGS,
genomic and clinical data are still mainly collected and studied in silos
by gene or disease, institution or country. Such a finding is consistent
with previous observations (Akle, Chun, Jordan, & Cassa, 2015) and
others in the Matchmaker Exchange Special Issue (Human Mutation,
Special Issue: The Matchmaker Exchange October 2015, Volume 36,
Issue 10, Pages i–iii, 915–1019). It can be explained by several factors,
including: regulatory data-privacy requirements which inhibit secure
data sharing across institutions and countries; poor rewarding of peo-
plewho collect ormake individual contributions to data collection; and
the incompatibility of file formats and nonstandardized tools and ana-
lytical methods (GA4GH, 2016). It is also worth noting that new NGS-
derived variants may often be “hidden” in the published literature, for
example, within a cohort identified by a broad diagnosis of intellectual
disability (Gilissen et al., 2014), without specific reference being made
(e.g., to RTT and/orMECP) in the title or abstract of an article. As a con-
sequence, many variants may not be picked up by database curators
when trawling the literature for new additions. It is neither the inten-
tion nor the recommendation of this article that one database should
collect and provide all data but it would be helpful if data could be inte-
grated and findable in such a way that a researcher does not have to
search multiple databases to look for one specific variant. In general,
adherence to FAIR principles and GA4GH guidelines promise a major
improvement.
4.2 Need for better sharing of data
(interoperability!) within and between RTT-relevant
databases
All of the databases tested in this study are accessible byWeb browser
(Graphical User Interface, GUI) but not all of them allow download of
search results. The lack of a proper API or download function limits
data exchangewithindifferent databaseswhich leads to the conclusion
that the interoperability of these databases is currently rather poor.
Making databases interoperable is of particular value as we found that
approaches to several databases may be required in order to locate
information about a specific mutation and/or to find all of the avail-
able phenotypic information. If these databases were generally able
to share and exchange data with each other (as some already do, e.g.,
DisGeNET—ClinVar, RettBase—LOVD), or meta-databases were avail-
able to simultaneously approach several databases through a single
search function, the search for information would bemuch easier.
There is a general problem with multiple entries of the same
patients or patient groups. Tracing back the submission to the same
author/research group can but may not mean that this is the same
patient cohort. As we saw in our database survey, the phenotypic data
entry varies greatly, such that multiple entries of the same patient
would not automatically be recognized as being the same data. Using
data about a patient more than once can lead to statistical bias,
especially in the field of rare diseases. For this reason, we would
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encourage the use of registry identifiers (e.g., ID-cards) or privacy pre-
serving record linkage (PPRL).
Patient data laws worldwide do not necessarily forbid uploading
genetic and phenotypic data to databases (as long as no personal
information is also shared), but medical doctors are not always aware
of what is permissible, and may opt to “play safe” by not upload-
ing data at all. Information and training for people who actually
produce the data (nonbioinformaticians) would, therefore, be helpful.
One such example is that started with the ELIXIR training platform
(https://www.elixir-europe.org/platforms/training), Bring Your Own
Data Workshops (BYOD https://www.dtls.nl/fair-data/byod/), and
several other initiatives.
Generally, there is a lack of time and funding to upload and main-
tain data. Here, we would encourage the community to make manda-
tory the publishing of datasets alongside the publishing of a research
article, as was startedwith gene-specific information (seeNucleic Acid
Research Instructions to Authors (Walker, Soll, Deutscher, Platt, &
Weiner, 1983)) and continued with raw transcriptomics data (jour-
nals require upload on databases like GEO or ArrayExpress before
publishing), and also to integrate the data in such a way that one
study needs to be uploaded only once and is then findable on other
platforms (such as BioStudies (McEntyre, Sarkans, & Brazma, 2015)).
Some positive steps are already being taken in this direction as many
European and national grants now require a data management plan
for new projects that will allow for sustainability after the project
ends.
These problems are not new but were, in fact, flagged up almost
10 years ago when the HVP was initiated (Cotton et al., 2008). At
that time, the late Dick Cotton recognized the need to “collect,
curate and make accessible information on all genetic variations
affecting human health,” and since then, many additional initiatives
have been started. To date, the most active and promising of these
is the founding of the Global Alliance for Genomics and Health
(GA4GH) in 2013. This offers a similar vision and complementary
philosophy and approach, with active Working groups and demon-
stration projects such as the Matchmaker Exchange and Beacon
project.
Another issue relates to the knowledge aggregation sites, reposi-
tories and in-house databases which require the owner's agreement
to input or download data from the database or grant permission on
a case-by-case basis when the request to access data is part of a spe-
cific research project with prior approval from amedical ethical board.
Such databases as the US NHS, Rett Database Network, InterRett,
AussieRett, and the Dutch Rett Database (Maastricht) are emerging
and there is a need to think about ways to connect them. For a start,
each entity must make sure that:
1. their database is populated by relevant and useful data (accurate,
up to date), which brings with it implications for data maintenance
and sustainability;
2. these data are findable and accessible, whichmay require reconsid-
eration of their access policy; and,
3. their database provides GUI and API infrastructure for connection
with others.
One option could be to use locally installable versions (instances) of
genotype-phenotype databases as offered by LOVD, or PhenomeCen-
tral (Phenotips). These in-house databases allow collection of patient
data and support (ontology) annotations of genetic and phenotype
information. Apart from supporting local data collection, exporting and
sharing of (non-patient specific!) meta-data can be made possible in a
second step.
4.3 The importance of being FAIR
In our study,we found that,with regard to findability and interoperabil-
ity of genotype–phenotype databases in particular, there is still much
to be done. There are initiatives thatwork on overcoming this problem.
The Beacon project of GA4GH is an initiative that seeks to link molec-
ular data by creating a common searchable infrastructure—the so-
called beacons. At the moment about 70 databases/data-sources con-
tribute to this. Currently, it is only possible to look for single nucleotide
changes—for example, a test search in Beacon for our mutation 1 (X:
153296882 G>A) yielded 13 hits. The search for small, specific inser-
tions/deletions is currently being implemented but is not yet func-
tional for all databases (personal communication). The RD-connect
and Orphanet platforms also provide data—in as much as they link
to registries and biobanks, which might have information about the
disease. For RTT, the RD-connect catalogue lists three registries: the
Italian National Rare Disease Registry, RaDiCo-GenIDA, and the Rett
Database Network (none of which provide directly available online
genetic and phenotypic data and were not, therefore, included in our
survey).
4.4 The importance of collecting detailed
phenotypic information
Among the genetic variants of MECP2, there are those that cause
RTT, those that cause mild intellectual disability, and there are neu-
tral/benign variants. Among the disease-causing forms, there are
severe and mild variants of typical/classical RTT and atypical RTT, for
example, preserved speech variant (Zappella et al., 2001). An underly-
ingminimal set of core and supporting criteriamust be fulfilled in order
for a clinical diagnosis of RTT to be given (Neul et al., 2010). Despite
this, however, both classical and atypical forms display a broad range of
phenotypes. To name but a few of the characteristics of the syndrome,
some individuals with RTT cannot walk while many do, and most
develop scoliosis or epilepsy but not all. Among those with epilepsy,
there is no single antiepileptic treatment that works for all, indicat-
ing for example, different physiological roots, although practice pref-
erences and availability of specific agents may also affect the choice of
medications. Mood and character of individuals vary greatly, too. It is
clear that RTT is a complex syndrome with multiple factors—including
levels of X-inactivation, genomic, epigenetic, and other environmental
influences—affecting its phenotypic presentation. Currently, there are
several approaches to capture the phenotype realized in the databases
we investigated:
1. By diagnosis: RTT- or disease-specific databases especially, give
the information that the carrier of this MECP2 mutation has been
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diagnosed with RTT (or others) (RettBase, ClinVar, Café Vari-
ome/PhenCode, DisGeNET, HGMD). In some cases, the diagnosis is
even linked to an identifier (OMIM,MeSH, DOID).
2. A detailed description of the phenotype is given—but without diag-
nosis (DECIPHER, HGMD).
3. The effect of the genetic variation is given as measured/observed
or predicted (e.g., using PolyPhen2) molecular biological
consequences (LOVD, ExAC, dbSNP) or phenotype “damaging”
effect (EVS).
To cover the richness of medical observation, we strongly encour-
age the collection of detailed phenotype descriptions of genetic
variations. One way to contribute to a more detailed elucidation of
phenotypes is throughencouraging a clearer use of termswhich should
include the use of ontologies, identifiers andminimal information stan-
dards (Lapatas, Stefanidakis, Jimenez, Via, & Schneider, 2015). In
this respect, the application of HPO terms is widely advocated
within the rare disease field/community, as illustrated by the GA4GH
recommendation on this topic (see https://genomicsandhealth.org/
working-groups/our-work/phenotype-ontologies). This is where
population-based/epidemiological studies such as the US NHS and
AussieRett, both of which track and record the longitudinal natural
history of RTT, couldmake amajor contribution in the future.
Finally, we would like to stress two things. First, we recognize that
any work such as we are recommending to further develop, main-
tain and integrate existing databases does not come without costs
attached. However, we believe that each of the databases we have
investigated in this study is of value and should be well-supported and
well-funded in order to maximize use of the data and yield maximum
long-term benefits. Second, we recognize that diseases are rarely truly
monogenic. All genes function in an environment of other gene prod-
ucts, including their variations (epistasis). In addition to classic exam-
ples, such as PKU (Scriver &Waters, 1999) and Cystic Fibrosis (Gallati,
2014), this was recently illustrated in the cancer field with the added
value of gene expression data to established oncogenic driver muta-
tions (Voest & Bernards, 2016). A similar argument was put forward
by McArthur and colleagues when they advocated for the inclusion of
RNA-seq to increase the diagnostic yield within the field of rare dis-
eases (Cummings et al., 2017). This phenomenon may also be trans-
lated to RTT with MECP2 mutations as major “drivers”. To read and
interpret a disease-causing variantwithin the individual's genetic envi-
ronment will be one of themajor challenges in the future.
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